TW267168B - - Google Patents

Info

Publication number
TW267168B
TW267168B TW83104895A TW83104895A TW267168B TW 267168 B TW267168 B TW 267168B TW 83104895 A TW83104895 A TW 83104895A TW 83104895 A TW83104895 A TW 83104895A TW 267168 B TW267168 B TW 267168B
Authority
TW
Taiwan
Application number
TW83104895A
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB939301000A priority Critical patent/GB9301000D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of TW267168B publication Critical patent/TW267168B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
TW83104895A 1993-01-20 1994-05-30 TW267168B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB939301000A GB9301000D0 (en) 1993-01-20 1993-01-20 Chemical compounds

Publications (1)

Publication Number Publication Date
TW267168B true TW267168B (zh) 1996-01-01

Family

ID=10728948

Family Applications (1)

Application Number Title Priority Date Filing Date
TW83104895A TW267168B (zh) 1993-01-20 1994-05-30

Country Status (29)

Country Link
US (2) US5925624A (zh)
EP (1) EP0680488B1 (zh)
JP (1) JP3768232B2 (zh)
KR (1) KR960700261A (zh)
CN (1) CN1043997C (zh)
AP (1) AP457A (zh)
AT (1) AT164849T (zh)
AU (1) AU679714B2 (zh)
CA (1) CA2153688A1 (zh)
CZ (1) CZ187995A3 (zh)
DE (2) DE69409503D1 (zh)
DK (1) DK0680488T3 (zh)
EC (1) ECSP941104A (zh)
ES (1) ES2117249T3 (zh)
FI (1) FI953489A (zh)
GB (1) GB9301000D0 (zh)
HU (1) HU211914A9 (zh)
IL (1) IL108372A (zh)
IS (1) IS4121A (zh)
NO (1) NO305603B1 (zh)
NZ (1) NZ259880A (zh)
PE (1) PE54194A1 (zh)
PL (1) PL309975A1 (zh)
RU (1) RU2129561C1 (zh)
SI (1) SI9400021A (zh)
SK (1) SK281229B6 (zh)
TW (1) TW267168B (zh)
WO (1) WO1994017090A1 (zh)
ZA (1) ZA9400335B (zh)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2163023T3 (es) * 1995-05-30 2002-01-16 Aventis Pharma Sa Derivados del 2-azabiciclo(2.2.1)heptano, su preparacion y su aplicacion.
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP3861413B2 (ja) * 1997-11-05 2006-12-20 ソニー株式会社 情報配信システム、情報処理端末装置、携帯端末装置
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PL344021A1 (en) * 1998-02-26 2001-09-24 Aventis Pharma Inc 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
DZ2805A1 (fr) 1998-06-02 2005-01-30 Cadus Pharmaceutical Corp Composition à pyrroloÄ2,,3dÜ pyrimidine et leurs usages.
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
WO1999067265A1 (en) * 1998-06-23 1999-12-29 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
JP2003531111A (ja) 1999-12-17 2003-10-21 アライアッド・ファーマシューティカルズ・インコーポレーテッド プロトンポンプインヒビター
KR100785363B1 (ko) * 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1939203B1 (en) * 2000-04-25 2014-11-19 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
JP4642309B2 (ja) * 2000-04-25 2011-03-02 イコス・コーポレイションIcos Corporation ヒトホスファチジル−イノシトール3−キナーゼデルタの阻害剤
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PE00082003A1 (es) * 2001-06-19 2003-01-22 Squibb Bristol Myers Co Inhibidores duales de pde 7 y pde 4
WO2003004511A2 (en) * 2001-07-06 2003-01-16 Topigen Pharmaceutique Inc.. Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
WO2003045968A1 (en) 2001-11-27 2003-06-05 Anadys Pharmaceuticals, Inc. 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
EP2050751A1 (en) 2001-11-30 2009-04-22 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
BR0215202A (pt) 2001-12-20 2004-10-13 Osi Pharm Inc Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
ES2237234B1 (es) * 2002-08-02 2006-11-01 Universidad De Oviedo Preparacion de (+) y (-)-trans-ciclopentano-1,2-diamina.
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0328319D0 (en) 2003-12-05 2004-01-07 Cambridge Biotechnology Ltd Improved synthesis of 2-substituted adenosines
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
EA011826B1 (ru) * 2004-05-26 2009-06-30 Инотек Фармасьютикалз Корпорейшн Пуриновые производные в качестве агонистов аденозиновых арецепторов и способы их применения
FR2874014B1 (fr) * 2004-08-03 2010-05-14 Univ Paris Descartes Analogues d'aminoglycosides, leur utilisation et leur synthese
NZ554723A (en) * 2004-10-29 2009-12-24 Topigen Pharmaceuticals Inc Antisense oligonucleotides against CCR3 chemokine receptor
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
JP5303149B2 (ja) 2004-12-17 2013-10-02 アナディス ファーマシューティカルズ インク 3,5−二置換及び3,5,7−三置換−3H−オキサゾロ及び3H−チアゾロ[4,5−d]ピリミジン−2−オン化合物及びそのプロドラッグ
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
PL2532679T3 (pl) 2005-10-21 2017-09-29 Novartis Ag Ludzkie przeciwciała przeciwko IL13 i zastosowania terapeutyczne
EP1973920B1 (en) 2005-11-21 2010-07-21 Anadys Pharmaceuticals, Inc. Process for the preparation of 5-amino-3h-thiazolo [4,5-d] pyrimidin-2-one
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0713680A2 (pt) 2006-06-22 2012-10-23 Anadys Pharmaceuticals Inc composto, composição farmacêutica e métodos de modulação das atividades imuno da citocina, de tratamento de infecção de vìrus da hepatite c em paciente e de tratamento de desordem de proliferação relacionada em mamìfero carecido do mesmo
JP5225991B2 (ja) 2006-07-18 2013-07-03 アナディス ファーマシューティカルズ インク チアゾロ[4,5−d]ピリミジンのカーボネート及びカルバメートプロドラッグ
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US8796241B2 (en) 2007-08-29 2014-08-05 Adam Lubin Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
ES2331867B1 (es) * 2008-07-17 2010-10-27 Entrechem, S.L. Sintesis enzimatica de derivados enantiomericamente enriquecidos de trans-ciclopentano- 1,2-diaminas.
KR20160091440A (ko) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
NZ595307A (en) 2009-03-24 2013-11-29 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
WO2010123931A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals Inc. Methods of treatment for solid tumors
EP2456443A1 (en) 2009-07-21 2012-05-30 Gilead Calistoga LLC Treatment of liver disorders with pi3k inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
WO2011022439A1 (en) 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
US8461328B2 (en) 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
CA2864305A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
KR20150001782A (ko) 2012-04-03 2015-01-06 노파르티스 아게 티로신 키나제 억제제들을 갖는 조합 제품 및 그의 용도
TW201918485A (zh) 2012-12-21 2019-05-16 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US9421214B2 (en) 2013-07-12 2016-08-23 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
MX2016008259A (es) 2013-12-20 2016-10-13 Gilead Calistoga Llc Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
CN106632339B (zh) * 2016-12-16 2018-11-27 温州医科大学 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789773A (fr) * 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
CA1239397A (en) * 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
EP0300144A3 (en) * 1984-04-18 1989-09-27 Whitby Research Incorporated N-6 alkyl substituted adenosine derivatives as cardiac vasodilators
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4757747A (en) * 1986-04-08 1988-07-19 Vickers, Incorporated Power transmission
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
EP0277917A3 (en) * 1987-02-04 1990-03-28 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
AT128141T (de) * 1988-03-16 1995-10-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
PT95628A (pt) * 1989-10-19 1991-09-30 Searle & Co Metodo de tratamento de perturbacoes de mobilidade gastrointestinal com composto de adenosina
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
DE4025879A1 (de) * 1990-08-16 1992-02-20 Sandoz Ag Neue adenosin derivate, deren herstellung und verwendung
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
WO1995002604A1 (en) * 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists

Also Published As

Publication number Publication date
US5925624A (en) 1999-07-20
NO305603B1 (no) 1999-06-28
NZ259880A (en) 1996-11-26
ES2117249T3 (es) 1998-08-01
NO952872L (no) 1995-09-13
ECSP941104A (es) 1994-12-15
FI953489A0 (fi) 1995-07-19
NO952872D0 (no) 1995-07-19
ZA9400335B (en) 1994-10-24
FI953489A (fi) 1995-09-13
DK680488T3 (zh)
IL108372A (en) 1998-06-15
CN1119440A (zh) 1996-03-27
KR960700261A (ko) 1996-01-19
SK91895A3 (en) 1996-04-03
PE54194A1 (es) 1995-01-06
GB9301000D0 (en) 1993-03-10
DK0680488T3 (da) 1999-01-25
AU5885194A (en) 1994-08-15
EP0680488B1 (en) 1998-04-08
CZ187995A3 (en) 1996-01-17
PL309975A1 (en) 1995-11-13
IS4121A (is) 1994-07-21
AT164849T (de) 1998-04-15
JPH08505864A (ja) 1996-06-25
HU211914A9 (en) 1996-01-29
SK281229B6 (sk) 2001-01-18
CA2153688A1 (en) 1994-08-04
AP457A (en) 1996-02-01
EP0680488A1 (en) 1995-11-08
IL108372D0 (en) 1994-04-12
WO1994017090A1 (en) 1994-08-04
SI9400021A (en) 1994-09-30
US5889178A (en) 1999-03-30
JP3768232B2 (ja) 2006-04-19
DE69409503D1 (de) 1998-05-14
AU679714B2 (en) 1997-07-10
CN1043997C (zh) 1999-07-07
FI953489D0 (zh)
DE69409503T2 (de) 1998-08-06
AP9400613A0 (en) 1994-01-31
RU2129561C1 (ru) 1999-04-27

Similar Documents

Publication Publication Date Title
DE9301553U1 (zh)
DE9300736U1 (zh)
DE9302092U1 (zh)
DE9302081U1 (zh)
DE9300663U1 (zh)
DE9301044U1 (zh)
DE9301499U1 (zh)
DE9300291U1 (zh)
DE9301132U1 (zh)
DE9300757U1 (zh)
DE9300962U1 (zh)
DE9300478U1 (zh)
DE9300711U1 (zh)
DE9301608U1 (zh)
DE9301298U1 (zh)
DE9300765U1 (zh)
DE9301268U1 (zh)
DE9300268U1 (zh)
DE9300928U1 (zh)
DE9300190U1 (zh)
DE9300160U1 (zh)
DE9301708U1 (zh)
DE9301994U1 (zh)
DE9301870U1 (zh)
DE9300447U1 (zh)